More Stories

Informist, Thursday, Feb. 5, 2026

 

Please click here to read all liners published on this story

--Max Health Oct-Dec consol net profit INR 3.01 bln
--Analysts saw Max Health Oct-Dec consol net profit at INR 3.88 bln
--Max Health Oct-Dec consol revenue INR 20.68 bln
--Analysts saw Max Health Oct-Dec consol revenue at INR 25.02 bln
--Max Health Oct-Dec consol PAT INR 3.01 bln vs INR 2.39 bln year ago
--Max Health Oct-Dec consol revenue INR 20.68 bln vs INR 18.68 bln yr ago
--Max Health Apr-Dec consol PAT INR 11.00 bln vs INR 7.57 bln yr ago
--Max Health Apr-Dec consol revenue INR 62.31 bln vs INR 51.19 bln yr ago
--Max Health Oct-Dec consol operating EBITDA INR 5.69 bln

 

By Narayana Krishna

 

HYDERABAD – Max Healthcare Institute Ltd. Thursday reported a consolidated net profit of INR 3.01 billion for the December quarter, up 26% on year but down nearly 39% sequentially. The company's revenue for the quarter was up nearly 11% on year but fell over 3% on quarter to INR 20.68 billion.

 

The healthcare service provider's net profit as well as revenue for the December quarter were below the Street estimates. Analysts had estimated Max Healthcare's net profit at INR 3.88 billion on a revenue of INR 25.02 billion.

 

Fall in occupancy and one-off costs hit Max Healthcare's December quarter performance. The company's overall hospital bed occupancy fell to 74% from 75% a year ago and 77% a quarter ago.

 

The company reported an exceptional cost of INR 482.4 million related to implementation of the new labour codes and stamp duty expenditure related to one of its subsidiaries.

 

The company's average revenue per occupied bed for the quarter improved to INR 77,900 from INR 75,900 a year ago. However, its operating margin for the December quarter was 26.1%, down from 27.3% a year ago, Max Healthcare said.

 

The network's operating margin was affected by pre-commissioning expenses of brownfield expansion at some hospitals, changes in goods and service tax rates, and discontinuation of some high value patented drugs used to treat chemotherapy patients in the institutional category, Max Health said.

The company's consolidated earnings before interest, tax, depreciation, and amortisation for the quarter was INR 5.69 billion. Its diagnostic services division Max Lab reported 13% year-on-year growth in revenue for the December quarter to INR 470 million while its home service division Max Home reported 23% year-on-year growth in revenue to INR 680 million, the company said.

 

The company's total expenses for the quarter rose nearly 12% on year to INR 17 billion. The finance cost rose nearly 14% on year to INR 596.7 million. The hospital chain's costs on account of professional and consultancy fees, mostly spent on doctors and healthcare professionals, rose 14.5% on year to INR 4.4 billion. Employee expenses, too, were up nearly 12% on year to INR 3.4 billion.

 

For the nine months ended Dec. 31, Max Healthcare Institute reported a consolidated net profit of INR 11 billion on a revenue of INR 62.31 billion. At 1513 IST, its shares were up 1.5% at INR 1,040.70 on the National Stock Exchange.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.